Open Respiratory Archives最新文献

{"title":"Combining Spirometry and the ARISCAT Respiratory Risk Assessment Can Improve Postoperative Outcomes and Reduce Mortality Risk in Mexico","authors":"Yolanda Mares-Gutiérrez ,&nbsp;Adrián Martínez-González ,&nbsp;Guillermo Salinas-Escudero ,&nbsp;Manuel García-Minjares ,&nbsp;Stephanie Liu ,&nbsp;Yvonne N. Flores","doi":"10.1016/j.opresp.2024.100325","DOIUrl":"10.1016/j.opresp.2024.100325","url":null,"abstract":"<div><h3>Introduction</h3><p>Although a major goal of preoperative evaluation is to identify risk factors and improve postoperative outcomes, current clinical guidelines in Mexico indicate that preoperative spirometry should only be performed on patients with pulmonary disease. The aim of this study was to compare the incidence of postoperative complications (POC), mortality, and risk factors among adults who did or did not undergo preoperative spirometry, based on their Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) risk level.</p></div><div><h3>Material and methods</h3><p>An observational, retrospective and comparative study design was used to identify 2059 patients from the <em>General Hospital of Mexico</em> who had an ARISCAT assessment during 2013–2017. Patients were classified in two groups: ARISCAT with spirometry (<em>n</em> <!-->=<!--> <!-->1306) and ARISCAT without spirometry (<em>n</em> <!-->=<!--> <!-->753). Chi-square, Fisher's exact test and the Student's <em>t</em>-tests were used to compare groups. Logistic regression was used to identify factors associated with an increased risk of POC and mortality.</p></div><div><h3>Results</h3><p>In the ARISCAT with spirometry group, 11% of patients had POC, compared with 48% of patients in the ARISCAT without spirometry group. High-risk ARISCAT patients who did not receive spirometry had higher mortality (18%), than those who underwent spirometry (0.4%). Logistic regression results indicate that not performing preoperative spirometry increases the probability of POC and mortality.</p></div><div><h3>Conclusions</h3><p>Our findings suggest that the combined use of preoperative spirometry and ARISCAT is associated with reduced POC and mortality. Future clinical guidelines should recommend the use of preoperative spirometry for patients with a moderate or high ARISCAT level in Mexico.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100325"},"PeriodicalIF":0.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000286/pdfft?md5=d0f326e798d3d29eb1cf10067ba775a3&pid=1-s2.0-S2659663624000286-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140779408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colaboración del farmacéutico comunitario en el infradiagnóstico de la enfermedad pulmonar obstructiva crónica (EPOC)","authors":"Francisco Javier Plaza Zamora ,&nbsp;Juan Marco Figueira-Gonçalves ,&nbsp;Javier de Miguel-Díez","doi":"10.1016/j.opresp.2024.100329","DOIUrl":"10.1016/j.opresp.2024.100329","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100329"},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000328/pdfft?md5=87187431e0964afb540c959d2b33b788&pid=1-s2.0-S2659663624000328-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140757221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights","authors":"Rafael López-Castro ,&nbsp;Álvaro Fuentes-Martín ,&nbsp;Andrea Medina del Valle ,&nbsp;Tania García Peña ,&nbsp;José Soro García ,&nbsp;Leticia López González ,&nbsp;Ángel Cilleruelo Ramos","doi":"10.1016/j.opresp.2024.100323","DOIUrl":"https://doi.org/10.1016/j.opresp.2024.100323","url":null,"abstract":"<div><p>MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its limited treatment choices and unfavorable prognosis. The advent of immune checkpoint inhibitors has heralded a paradigm shift in the therapeutic landscape of MPM, offering promising avenues across diverse clinical scenarios. In the context of advanced stages of the disease, Immune check-point inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-as-sociated protein 4 (CTLA-4), have exhibited encouraging potential in clinical trials, particularly manifesting efficacy among patients exhibiting disease progression following chemotherapy regimens. Innovative combination regimens, exemplified by the concurrent administration of nivolumab and ipilimumab, have demonstrated marked improvement in survival and patient's benefits. A deeper comprehension of the intricate genetic underpinnings of MPM, encompassing key mutations such as cyclin-dependent kinase inhibitor 2A (CDKN2A), neurofibromin 2 (NF2), and BRCA1-associated protein 1 (BAP1) mutations, has elucidated novel avenues for targeted therapeutic interventions. This review accentuates the transformative capacity of immunotherapy in revolutionizing the therapeutic outlook for MPM, thereby potentially translating into augmented survival rates and offering glimpses of new approaches on the horizon. Despite the persisting challenges, the synergistic crossroads of interdisciplinary research and collaborative clinical endeavors portend a hopeful landscape for MPM treatment.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100323"},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000262/pdfft?md5=c0973982c927d446d5a17c9dbccebafb&pid=1-s2.0-S2659663624000262-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140633480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asma","authors":"Celia Pinedo Sierra ,&nbsp;Elena Curto Sánchez ,&nbsp;Rocio Diaz Campos ,&nbsp;Tamara Hermida Valverde ,&nbsp;Silvia Sánchez-Cuellar ,&nbsp;Ana Fernández Tena","doi":"10.1016/j.opresp.2024.100324","DOIUrl":"https://doi.org/10.1016/j.opresp.2024.100324","url":null,"abstract":"<div><p>Asthma is a chronic inflammatory disease that affects about 5% of the world's population and generates high health and social costs. Proper management of the disease requires a correct diagnosis, based on objective measures of functional impairment, as well as symptom control and assessment of the future risk of exacerbations.</p><p>It has been estimated that 18% of asthma patients in Western Europe have severe asthma and approximately 50% of them have poor control. The severity of asthma is established based on the minimum maintenance treatment needs to achieve control. Asthma clinical practice guidelines recommend classifying severe patients into allergic asthma (T2); eosinophilic asthma (T2) and non-T2 asthma in order to establish the most appropriate treatment.</p><p>In recent decades, new biological therapies have been developed that can be applied according to the phenotype and endotype of asthma, allowing for selective and personalized treatment. These phenotypes and endotypes can change over time and therefore, the identification of biomarkers capable of predicting the severity, the course of the disease and the response to a given treatment seems essential. A large number of biomarkers have been studied in asthma, but so far only a few can be readily used in routine clinical practice. The application of omics technologies (epigenomics, genomics, transcriptomics, proteomics, metabolomics, lipidomics, etc.) for this purpose is still in the research phase.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 2","pages":"Article 100324"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000274/pdfft?md5=da83182976efb08c6744a01259b8601b&pid=1-s2.0-S2659663624000274-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade","authors":"Fernando Garcia-Prieto ,&nbsp;Sara Calero Pardo ,&nbsp;María Teresa Río Ramírez ,&nbsp;Araceli Abad Fernández","doi":"10.1016/j.opresp.2024.100326","DOIUrl":"10.1016/j.opresp.2024.100326","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 2","pages":"Article 100326"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000298/pdfft?md5=a905f3cb4ba467799e4586b3d6691ae4&pid=1-s2.0-S2659663624000298-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140774146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Terapias respiratorias domiciliarias: documento técnico de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) de apoyo institucional a la toma de decisiones","authors":"Pedro J. Marcos ,&nbsp;Alberto Fernández Villar ,&nbsp;Eduardo Márquez Martín ,&nbsp;María Teresa Ramírez Prieto ,&nbsp;Irene Cano Pumarega","doi":"10.1016/j.opresp.2024.100318","DOIUrl":"10.1016/j.opresp.2024.100318","url":null,"abstract":"<div><p>Home Respiratory Therapies (HRT) encompass a variety of treatments for patients with chronic respiratory diseases, administered at home over extended periods. The Service Providers of HRT (SPHRT) collaborate with hospital resources to address chronic respiratory diseases, acting as strategic partners. The contracting of HRT in the public health system involves contests where the SPHRT present technical and economic offers. The purpose of this document is to provide a technical basis that can assist professionals, SPHRT, and the administration in making decisions when calling for, evaluating, and deciding on such contests.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 2","pages":"Article 100318"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000213/pdfft?md5=68df135bc3821de51b62c8056e9588cd&pid=1-s2.0-S2659663624000213-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients’ Beliefs About Medicines and Adherence to Inhalers","authors":"Eduardo Garcia-Pachon ,&nbsp;Justo Grau-Delgado ,&nbsp;Carlos Baeza-Martínez ,&nbsp;Lucía Zamora-Molina ,&nbsp;Marta Galán-Negrillo ,&nbsp;Marina Beléndez-Vázquez","doi":"10.1016/j.opresp.2024.100322","DOIUrl":"https://doi.org/10.1016/j.opresp.2024.100322","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 2","pages":"Article 100322"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000250/pdfft?md5=ddf8096f371c65b3109606e354a3eb9a&pid=1-s2.0-S2659663624000250-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140638792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Effects on Elderly People From Nirsevimab Use in Infants","authors":"Iván Sanz-Muñoz ,&nbsp;Javier Castrodeza-Sanz ,&nbsp;José M. Eiros","doi":"10.1016/j.opresp.2024.100320","DOIUrl":"10.1016/j.opresp.2024.100320","url":null,"abstract":"<div><p>Nirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It is true that some studies link the use of nirsevimab to a reduction in the virus's ability to spread by lowering the viral load in infants as a result of the drug's long half-life. However, this protective effect may not be very significant because RSV transmission in the elderly typically comes from other elderly people or from school-aged children. Furthermore, RSV may be transmitted at any time of the year and not just during the period of nirsevimab protection due to its existence in human reservoirs. The reasons made here show that, even though nirsevimab treatment in infants may protect the elderly, this benefit would be limited and testimonial. Therefore, immunizing the elderly with currently licensed and developing vaccines should be a priority.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 2","pages":"Article 100320"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000237/pdfft?md5=f4fcec8f7471df144b7c9c1558b6fc33&pid=1-s2.0-S2659663624000237-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140270988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Encuesta sobre la actividad de los laboratorios de función pulmonar. Efectos durante la pandemia por SARS-CoV-2","authors":"Laura Vigil Giménez ,&nbsp;Juana Martínez Llorens ,&nbsp;Karina Portillo Carroz ,&nbsp;Rocío García García ,&nbsp;Francisco Ortega Ruiz ,&nbsp;Luis Puente Maestu ,&nbsp;en representación del Grupo de Trabajo","doi":"10.1016/j.opresp.2024.100315","DOIUrl":"10.1016/j.opresp.2024.100315","url":null,"abstract":"<div><h3>Introduction</h3><p>Following the SARS-CoV-2 pandemic in March 2020, pulmonary function testing (PFT) laboratories underwent a transformation, with a reduction in the number of tests or closure in some cases. The aim of this work was to know the activity of PFT in Spain and the modification of this activity due to the pandemic.</p></div><div><h3>Material and methods</h3><p>A protocolised survey was carried out to members of the PFT laboratories through the Spanish Society of Pneumology and Thoracic Surgery (SEPAR).</p></div><div><h3>Results</h3><p>Thirty-nine hospitals in Spain responded. The pulmonary function tests most frequently performed in the PFT laboratories were forced spirometry with bronchodilator test (100%), body plethysmography (97.4%), CO transfer capacity (97.4%), respiratory muscle strength measured in the mouth (97.4%), 6-minute walking test (94.7%), measurement of exhaled fraction of nitric oxide (92.3%) and incremental exercise test (71.8%).</p><p>The pandemic led to a significant decrease in the number of tests (35.4%) during 2020 with subsequent recovery in 2021, without reaching pre-pandemic values.</p><p>The most important changes were increased examination times, working with personal protective equipment and ventilation of the rooms. The performance of the nasopharyngeal swab for SARS-CoV2 testing prior to the tests was not homogeneous in the PFT laboratories.</p></div><div><h3>Conclusions</h3><p>Most hospitals are sufficiently equipped to perform the most common pulmonary function tests. The pandemic resulted in a loss of activity in all hospitals.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 2","pages":"Article 100315"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000183/pdfft?md5=b4154b74ab3598cfc83bded8a4af1865&pid=1-s2.0-S2659663624000183-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Natural History of Severe Chronic Obstructive Pulmonary Disease: The SPOCCAT Study Protocol","authors":"Jessica González ,&nbsp;Dan Sánchez ,&nbsp;Daniel Ross-Monserrate ,&nbsp;Elena Miguel ,&nbsp;Marc Miravitlles ,&nbsp;Roser Costa ,&nbsp;on behalf of the SPOCCAT study","doi":"10.1016/j.opresp.2024.100321","DOIUrl":"https://doi.org/10.1016/j.opresp.2024.100321","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with severe chronic obstructive pulmonary disease (COPD) are often underrepresented in cohorts, creating uncertainty about the natural history and prognostic factors of this subgroup. Our goal was to describe the SPOCCAT (Severe COPD: Prospective Observational study of COPD in Catalonia) study protocol.</p></div><div><h3>Material and methods</h3><p>SPOCCAT is a non-interventional, multicenter, prospective cohort study of patients with severe COPD (FEV₁% predicted<!--> <!-->&lt;<!--> <!-->50%). The study aims to: (1) establish a five-year prospective cohort; (2) identify demographic and clinical characteristics; (3) describe treatment patterns; (4) better understand the natural history of severe COPD, including lung function decline, exacerbation rates, and mortality; and (5) identify prognostic factors for poor outcomes.</p><p>Recruitment began in January 2024, and the cohort will be followed for a minimum of five years (or until death or lung transplant) with follow-up visits every 12 months. Baseline data include demographics, laboratory analyses, comorbidities, lung function, respiratory symptoms, respiratory disease exacerbations and etiology, quality of life, physical activity, chest computed tomography, and treatment. Annual follow-up visits will assess changes in treatment, exacerbation frequency and severity, microbiological outcomes, complementary tests, and mortality. Participation requires written informed consent from all patients, with data collected in an anonymized electronic Case Report Form.</p></div><div><h3>Results</h3><p>The results of the SPOCCAT study will provide relevant information about the characteristics, treatment, and prognostic factors of severe COPD.</p></div><div><h3>Conclusions</h3><p>SPOCCAT has the potential to enhance understanding of severe COPD, exploring innovative aspects and establishing a robust research framework for future COPD-related projects.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 2","pages":"Article 100321"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000249/pdfft?md5=72ad9e7d25582f67c17023fc3c46d0e8&pid=1-s2.0-S2659663624000249-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140638791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}